Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

BCX17725

Small molecule · developed by BioCryst Pharmaceuticals

Phase 1 Most advanced trial
BCRX Developer
1 Registered trials

What is BCX17725?

BCX17725 is a drug studied in Netherton Syndrome, a rare inherited skin disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Dermatology
Developer
BioCryst Pharmaceuticals (BCRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06539507 Phase 1 Netherton Syndrome Recruiting BCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Netherton Syndrome

More from BioCryst Pharmaceuticals

Berotralstat FDA approved Peramivir FDA approved Avoralstat Phase 3 BCX10013 Phase 1 Forodesine Phase 1/2 Galidesivir Phase 1 Pelecopan Phase 2 Ulodesine Phase 2

Follow BCRX, the company behind BCX17725

See BCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BCRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.